Key Points One intravenous dose of oncolytic VSV has single-agent activity in patients with relapsed refractory T-cell lymphoma. Direct oncolytic tumor cell killing and subsequent immune cell activation were observed,… Click to show full abstract
Key Points One intravenous dose of oncolytic VSV has single-agent activity in patients with relapsed refractory T-cell lymphoma. Direct oncolytic tumor cell killing and subsequent immune cell activation were observed, resulting in durable remissions in responding patients.
Keywords:
cell;
oncolytic vsv;
cell lymphoma;
relapsed refractory;
refractory cell;
patients relapsed
Journal Title: Blood Advances
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Blood Advances
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!